Company news

Radiopharm Theranostics Limited news in 2025

Radiopharm Theranostics Limited's news releases, calls and decks from 2025, newest first.

View company

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

December 15, 2025

RAD101 interim Phase 2b data - 92% achieve primary endpoint

December 14, 2025

Amendment to Annual Report by Foreign Issuer (Form 20-F/A)

December 10, 2025

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

November 18, 2025

RAD Approval for Phase 1 Therapeutic Trial of RAD 402

November 17, 2025

Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

November 17, 2025

RAD Announces 50% Enrollment in Phase 2b Trial of RAD101

November 16, 2025

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

November 12, 2025

RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204

November 11, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

November 5, 2025

RADX: Program and Financial Updates

November 3, 2025

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 31, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 29, 2025

Prospectus

October 20, 2025

RAD completes A$35 M Placement and launches A$5 M SPP

October 19, 2025

Trading Halt

October 15, 2025

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial

October 1, 2025

Radiopharm received approval for RAD 202 trial acceleration

September 30, 2025

SPL: Research & Option Agreement with Radiopharm Theranostics

September 30, 2025

Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)

September 18, 2025

Appendix 4E and Preliminary Final Report

August 29, 2025

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

July 29, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

July 28, 2025

RAD receives IND approval from US FDA for Betabart (RV-01)

July 27, 2025

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

July 22, 2025

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

June 24, 2025

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

June 11, 2025

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

June 10, 2025

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

June 4, 2025

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

June 3, 2025

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

June 2, 2025

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

June 1, 2025

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

May 19, 2025

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

May 12, 2025

Acceleration of RAD204 Phase 1 dose escalation trial

May 11, 2025

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

May 7, 2025

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis

April 28, 2025

First patient dosed in Phase IIb imaging for Brain Mets

April 27, 2025

New RAD202 data confirms positive tumor uptake

March 16, 2025

Half Year Report and Appendix 4D 31 December 2024

February 28, 2025

Clinical trial data shows RAD 101 detects Brain Metastases

February 9, 2025

Lantheus increases shareholding in RAD with A$8m placement

January 9, 2025

Decks in 2025